罗沙司他治疗非透析慢性肾脏病患者肾性贫血的疗效观察  

Efficacy of roxadustat on renal anemia in patients with non-dialysis chronic kidney disease

作　　者：敖利娜 解德琼[1] 唐前容 张臣丽[1] 朱磊[1] AO Li-na;XIE De-qiong;TANG Qian-rong;ZHANG Chen-li;ZHU Lei(Department of Nephrology,the Secotid People's Hospital of Yibin,Yibin,Sichuan 644000 China)

机构地区：[1]宜宾市第二人民医院肾内科,四川宜宾644000

出　　处：《中华实用诊断与治疗杂志》2021年第7期732-734,共3页Journal of Chinese Practical Diagnosis and Therapy

基　　金：四川省卫生和计划生育委员会科研课题(17PJ092)。

摘　　要：目的比较罗沙司他、重组人红细胞生成素治疗非透析慢性肾脏病(chronic kidney disease, CKD)患者肾性贫血的效果及安全性。方法 102例非透析CKD患者,2018年12月前确诊肾性贫血者51例为对照组,2018年12月后确诊肾性贫血者51例为观察组,比较2组一般资料。在规范治疗CKD及对症支持治疗基础上,对照组给予重组人红细胞生成素皮下注射,观察组给予罗沙司他口服,治疗8周后评定2组治疗效果。随访至2020年6月30日,比较2组不良事件及药物不良反应发生情况。结果 2组年龄、性别比例、体质量指数、合并高血压及糖尿病比率、CKD分期、估算肾小球滤过率、血红蛋白水平比较差异均无统计学意义(P>0.05)。观察组治疗总有效率(98.04%)与对照组(94.12%)比较差异无统计学意义(P>0.05)。102例患者均未失访,观察组随访期间不良事件发生率(3.92%)低于对照组(15.69%)(P<0.05),药物不良反应发生率(5.88%)与对照组(13.73%)比较差异无统计学意义(P>0.05)。结论非透析CKD患者发生肾性贫血后应用罗沙司他治疗可取得与重组人红细胞生成素相同的效果,且不良事件发生率较低。Objective To compare the efficacy and safety of roxadustat versus recombinant human erythropoietin in the treatment of renal anemia in patients with non-dialysis chronic kidney disease(CKD).Methods In 102 patients with non-dialysis CKD,51 patients were diagnosed before December,2018(control group)and 51 patients were diagnosed after December,2018(observation group).The general data were compared between two groups.Besides standard therapy of CKD and symptomatic and supportive therapy,observation group was given rosadustat orally,and control group was given subcutaneous injection of recombinant human erythropoietin.After 8 weeks of treatment,the therapeutic efficacies were evaluated in two groups.The patients were followed up till June 30,2020.The incidences of adverse events and drug adverse reactions were compared between two groups.Results There were no significant differences in the age,gender ratio,body mass index,percentages of hypertension and diabetes mellitus,CKD stages,estimated glomerular filtration rate and hemoglobin level between two groups(P>0.05).There was no significant difference in the total effective rate between observation group(98.04%)and control group(94.12%)(P>0.05).All 102 patients were followed up.The incidence of adverse events was lower in observation group(3.92%)than that in control group(15.69%)(P<0.05),and the incidence of drug adverse reactions showed no significant difference between observation group(5.88%)and control group(13.73%)(P>0.05).Conclusion Roxadustat achieves the same efficacy with recombinant human erythropoietin on renal anemia in patients with non-dialysis CKD,and the incidence of adverse events is low.

关 键 词：慢性肾脏病 肾性贫血 罗沙司他 重组人红细胞生成素 

分 类 号：R692[医药卫生—泌尿科学] R556[医药卫生—外科学]